SCHEMBL11943874

SCHEMBL11943874

O=c1c(OC2Cc3ccccc3C2)c(N2CCN(S(=O)(=O)c3cccs3)CC2)cnn1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GCKR Q14397 5/20 0.47
▸ GCK P35557 1/20 0.47
▸ NPC1 O15118 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945053 0.87 POLB (0.46) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11943935 0.86 THRB (0.51) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11943927 0.85 MEN1 (0.56) NPC1USP2MAPK1MAPTMEN1
SCHEMBL11944424 0.83 SMN1; SMN2 (0.48) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11945000 0.83 MAPT (0.48) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11944992 0.83 MAPT (0.46) MAPTKMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL11943888 0.79 MAPT (0.61) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11943887 0.79 MAPK1 (0.53) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11944000 0.78 POLB (0.47) NPC1USP2MAPK1MAPTJAK2
SCHEMBL11945015 0.77 MAPT (0.47) NPC1USP2MAPK1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA GCKR 333/4885GCK 91/4885NPC1 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback